What is the address of DR. CARLOS MONTÉ, NEUROLOGIE?

The registered office of DR. CARLOS MONTÉ, NEUROLOGIE is located at Provinciebaan 252, 9620 Zottegem.

Is DR. CARLOS MONTÉ, NEUROLOGIE still active?

Yes. According to the CBE (18 September 2026) DR. CARLOS MONTÉ, NEUROLOGIE is active, legal situation “Normale toestand”, started on 23 November 2016.

Is DR. CARLOS MONTÉ, NEUROLOGIE registered on Peppol?

No, DR. CARLOS MONTÉ, NEUROLOGIE is currently not registered on the Peppol network.

What is the enterprise number of DR. CARLOS MONTÉ, NEUROLOGIE?

The enterprise number of DR. CARLOS MONTÉ, NEUROLOGIE is BE0666602806.

When was DR. CARLOS MONTÉ, NEUROLOGIE founded?

DR. CARLOS MONTÉ, NEUROLOGIE was founded on 23 November 2016.

Who are the directors of DR. CARLOS MONTÉ, NEUROLOGIE?

According to the 2024 annual accounts, the directors of DR. CARLOS MONTÉ, NEUROLOGIE are: Carlos Monté.

Is DR. CARLOS MONTÉ, NEUROLOGIE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 23 November 2016; 4 annual accounts filed, latest fiscal year 2024; 1 directors known from the annual account.

How much profit did DR. CARLOS MONTÉ, NEUROLOGIE make in 2024?

DR. CARLOS MONTÉ, NEUROLOGIE posted a profit after taxes of € 11,513 in financial year 2024.

What is the revenue of DR. CARLOS MONTÉ, NEUROLOGIE?

As a small company, DR. CARLOS MONTÉ, NEUROLOGIE is not required to publish revenue in its annual accounts. In financial year 2024, its added value was € 81,064.

DR. CARLOS MONTÉ, NEUROLOGIE (Private Limited) - Zottegem

Dossier DR. CARLOS MONTÉ, NEUROLOGIE, printed on 18 September 2026 from databakkes.be/en/0666602806/dr-carlos-monte-neurologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2024

DR. CARLOS MONTÉ, NEUROLOGIE from Zottegem, company number BE0666602806, closed financial year 2024 with a result of € 11,513 after tax. For that financial year DR. CARLOS MONTÉ, NEUROLOGIE recorded a gross margin of € 81,064 and equity of € 203,657. Compared with financial year 2023, the result moved from € 15,512 to € 11,513. The company is profitable. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2025.

What it is worth Healthy

€ 203,657

▼ 9% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 11,513

▼ 26% vs 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 331,486

▲ 250% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 30,619 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2024

Vehicles and equipment

€ 2,668

▼ 39% vs 2023

Book value of vehicles, furniture and equipment.

Debts at end 2024

Bank debt ≈ 11 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 214,852

▲ 96% vs 2023

€ 18,780 is repaid this year. At this pace the long-term loan is gone in ≈ 11 years.

Owed to suppliers

€ 13,418

▲ 3% vs 2023

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 14,799

▼ 34% vs 2023

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Gross margin	€ 132,595 Gross margin 2021: € 132,595 First fiscal year in the series	€ 80,552 Gross margin 2022: € 80,552 ▼ 39% vs 2021 (€ 132,595) Unfavourable step	€ 85,073 Gross margin 2023: € 85,073 ▲ 6% vs 2022 (€ 80,552) Favourable step	€ 81,064 Gross margin 2024: € 81,064 ▼ 5% vs 2023 (€ 85,073) Unfavourable step	▼ 5%
Profit after taxes	€ 52,401 Profit after taxes 2021: € 52,401 First fiscal year in the series	€ 26,534 Profit after taxes 2022: € 26,534 ▼ 49% vs 2021 (€ 52,401) Unfavourable step	€ 15,512 Profit after taxes 2023: € 15,512 ▼ 42% vs 2022 (€ 26,534) Unfavourable step	€ 11,513 Profit after taxes 2024: € 11,513 ▼ 26% vs 2023 (€ 15,512) Unfavourable step	▼ 26%
Equity	€ 316,198 Equity 2021: € 316,198 First fiscal year in the series	€ 255,397 Equity 2022: € 255,397 ▼ 19% vs 2021 (€ 316,198) Unfavourable step	€ 222,763 Equity 2023: € 222,763 ▼ 13% vs 2022 (€ 255,397) Unfavourable step	€ 203,657 Equity 2024: € 203,657 ▼ 9% vs 2023 (€ 222,763) Unfavourable step	▼ 9%
Total debts	€ 329,027 Total debts 2021: € 329,027 First fiscal year in the series	€ 353,957 Total debts 2022: € 353,957 ▲ 8% vs 2021 (€ 329,027) Unfavourable step	€ 310,489 Total debts 2023: € 310,489 ▼ 12% vs 2022 (€ 353,957) Favourable step	€ 413,813 Total debts 2024: € 413,813 ▲ 33% vs 2023 (€ 310,489) Unfavourable step	▲ 33%
Cash	€ 228,031 Cash 2021: € 228,031 First fiscal year in the series	€ 186,462 Cash 2022: € 186,462 ▼ 18% vs 2021 (€ 228,031) Unfavourable step	€ 94,640 Cash 2023: € 94,640 ▼ 49% vs 2022 (€ 186,462) Unfavourable step	€ 331,486 Cash 2024: € 331,486 ▲ 250% vs 2023 (€ 94,640) Favourable step	▲ 250%
Land & buildings	€ 142,604 Land & buildings 2021: € 142,604 First fiscal year in the series	€ 211,258 Land & buildings 2022: € 211,258 ▲ 48% vs 2021 (€ 142,604) Unchanged	€ 207,881 Land & buildings 2023: € 207,881 ▼ 2% vs 2022 (€ 211,258) Unchanged	€ 196,401 Land & buildings 2024: € 196,401 ▼ 6% vs 2023 (€ 207,881) Unchanged	▼ 6%
Retained profit	€ 296,198 Retained profit 2021: € 296,198 First fiscal year in the series	€ 235,397 Retained profit 2022: € 235,397 ▼ 21% vs 2021 (€ 296,198) Unfavourable step	€ 202,763 Retained profit 2023: € 202,763 ▼ 14% vs 2022 (€ 235,397) Unfavourable step	€ 183,657 Retained profit 2024: € 183,657 ▼ 9% vs 2023 (€ 202,763) Unfavourable step	▼ 9%
Dividend	€ 0 Dividend 2021: € 0 First fiscal year in the series	€ 87,335 Dividend 2022: € 87,335 Unchanged (€ 0) Unchanged	€ 48,145 Dividend 2023: € 48,145 ▼ 45% vs 2022 (€ 87,335) Unchanged	€ 30,619 Dividend 2024: € 30,619 ▼ 36% vs 2023 (€ 48,145) Unchanged	▼ 36%
Bank debt	€ 142,821 Bank debt 2021: € 142,821 First fiscal year in the series	€ 130,273 Bank debt 2022: € 130,273 ▼ 9% vs 2021 (€ 142,821) Favourable step	€ 109,510 Bank debt 2023: € 109,510 ▼ 16% vs 2022 (€ 130,273) Favourable step	€ 214,852 Bank debt 2024: € 214,852 ▲ 96% vs 2023 (€ 109,510) Unfavourable step	▲ 96%
Balance sheet total	€ 645,225 Balance sheet total 2021: € 645,225 First fiscal year in the series	€ 609,354 Balance sheet total 2022: € 609,354 ▼ 6% vs 2021 (€ 645,225) Unchanged	€ 533,252 Balance sheet total 2023: € 533,252 ▼ 12% vs 2022 (€ 609,354) Unchanged	€ 617,470 Balance sheet total 2024: € 617,470 ▲ 16% vs 2023 (€ 533,252) Unchanged	▲ 16%

Key figures of DR. CARLOS MONTÉ, NEUROLOGIE, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to DR. CARLOS MONTÉ, NEUROLOGIE?

What happened at DR. CARLOS MONTÉ, NEUROLOGIE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 30, 2025 New annual accounts for financial year 2024: profit of € 11,513 (▼ 26% vs 2023). filed late Source: NBB ↗
Nov 23, 2016 New establishment in Zottegem. KBO
Nov 23, 2016 Start of the company according to the CBE. KBO

In short

From € 52,401 profit in 2021 to € 11,513 profit in 2024.

Paid € 43,535 in corporate taxes since 2021.

Best year ever: 2021, with € 52,401 profit.

Paid out € 166,099 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at DR. CARLOS MONTÉ, NEUROLOGIE? We notify you, reason included.

Follow DR. CARLOS MONTÉ, NEUROLOGIE

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Carlos Monté

DR. CARLOS MONTÉ, NEUROLOGIE

Behind DR. CARLOS MONTÉ, NEUROLOGIE is Carlos Monté.

See the full network in the app

Directors

According to the 2024 annual accounts

Carlos Monté

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Provinciebaan 252

9620 Zottegem

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0666.602.806
VAT number: BE 0666.602.806
Registered office: Provinciebaan 252, 9620 Zottegem
Names & denominations: DR. CARLOS MONTÉ, NEUROLOGIE
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 23 November 2016
Peppol: Not registered

View on CBE Public ↗ Annual accounts (NBB) ↗